Navigation Links
Experimental Drug Shows Promise Against Type 2 Diabetes
Date:2/27/2012

SUNDAY, Feb. 26 (HealthDay News) -- An experimental drug improves patients' blood sugar control without increasing the risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, according to the results of a phase 2 clinical trial.

Type 2 diabetes is the more prevalent form of the disease, accounting for about 90 percent of cases. Often tied to obesity, type 2 diabetes involves a gradual decline in how insulin responds to changes in blood sugar (glucose).

The new drug, called TAK-875, is a pill designed to enhance the secretion of insulin in response to such changes, which means that it has no effect on insulin secretion when blood sugar levels are normal -- potentially reducing the risk for hypoglycemia.

The trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.

The patients were randomly assigned to receive either TAK-875 (303 patients), placebo (61 patients), or another diabetes drug called glimepiride (brand named Amaryl).

The study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.

After 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said. A similar reduction occurred in patients taking glimepiride.

However, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).

The incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers. They write that they are "excited about the potential of TAK-875 and are eager to conduct larger trials to find out how well this drug works, how safe it is and what its place is in the treatment of diabetes."

In a journal commentary, Clifford Bailey of Aston University in Birmingham, England, cautioned that, "on the journey to approval of a new class of treatment for type 2 diabetes, many questions will be asked of [drugs such as TAK-875]," including questions of how long they might remain effective, as well as safety issues.

Other diabetes experts had mixed views on the new findings.

Dr. Loren Wissner Greene is clinical associate professor of endocrinology at NYU Langone Medical Center in New York City. She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (Avandia was recently withdrawn from the U.S. market due to heart risks).

As for TAK-875, it targets a separate mechanism "but again, until more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism," Wissner Greene said.

Dr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, "given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents."

She said that, "though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain. However, like Wissner-Greene, Sood said that "further investigation is warranted, especially including [heart disease] patients."

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.

-- Robert Preidt

SOURCE: Loren Wissner Greene, MD, clinical associate professor, endocrinology, NYU Langone Medical Center, New York City; Minisha Sood, MD, endocrinologist, Lenox Hill Hospital, New York City ; The Lancet, news release, Feb. 24, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. First-in-human drug for malignant glioma available in experimental trial
2. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
3. Experimental Drugs Do Battle Against Advanced Prostate Cancer
4. Experimental Blood Thinner Given Before Surgery Shows Benefit
5. Wolfson Foundation awards £20 million to UCL for experimental neurology center
6. Novel experimental agent is highly active in CLL patients, interim study shows
7. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
8. Experimental Drug Slims Obese Monkeys
9. Experimental Psoriasis Drug Bests Older Treatment
10. Experimental Vaccine Shows Promise for Lung Cancer: Study
11. Experimental vaccine protects monkeys from blinding trachoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Shows Promise Against Type 2 Diabetes
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... with offices serving communities in northern Alabama and Georgia, is embarking on an ... prevention by utilizing modern early detection methods. , US Breast Cancer statistics ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete Coatings announced that ... rely on safety and cleanliness. This unique flooring system uses silver ion technology ... for centuries for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
(Date:9/20/2017)... Cleveland, Ohio (PRWEB) , ... September 20, 2017 ... ... commitment to customer service and innovation, the company recently unveiled a redesigned website. ... to further enrich the work of building owners, architects, contractors and other industry ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot Company is ... goal is to ignite conversation via social media and word-of-mouth regarding vaginal health, ... declared September “Humans with Vaginas” month, releasing a video celebrating the power of ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Just 18 months after its February 2016 launch, market ... appointment of three new senior people to its rapidly ... and James Wright bring decades of ... Tammy Wynne joins as Director, Value ... has over ten years, experience in global market access ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
(Date:8/25/2017)... -- Innovation Zed ( www.innovationzed.com ), an Irish medtech company, today announced that ... and Bassetlaw, England . The ... as part of a national NHS Test Bed programme exploring new models ... Innovation Zed ... InsulCheck Connect, a snap-on accessory for disposable insulin pen users, automatically collects ...
Breaking Medicine Technology: